Healthcare provider profile · identity verified

Sean J Rodriguez, MD

Family Practice · CHULA VISTA, CA · NPI 1780909903

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	283	80
Gabapentin	Gabapentin	225	63
Amlodipine Besylate	Amlodipine Besylate	176	55
Losartan Potassium	Losartan Potassium	166	42
Tamsulosin Hcl	Tamsulosin Hcl	161	47
Lisinopril	Lisinopril	160	41
Metformin Hcl	Metformin Hcl	160	50
Omeprazole	Omeprazole	157	50
Pravastatin Sodium	Pravastatin Sodium	126	34
Albuterol Sulfate Hfa	Albuterol Sulfate	121	30
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	114	24
Levothyroxine Sodium	Levothyroxine Sodium	98	25
Ozempic	Semaglutide	80	15
Famotidine	Famotidine	75	28
Fluticasone Propionate	Fluticasone Propionate	74	34
Trulicity	Dulaglutide	71	16
Tramadol Hcl	Tramadol Hcl	70	21
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	68	12
Hydrochlorothiazide	Hydrochlorothiazide	68	24
Diclofenac Sodium	Diclofenac Sodium	67	27
Pantoprazole Sodium	Pantoprazole Sodium	65	20
Glipizide	Glipizide	61	17
Allopurinol	Allopurinol	57	15
Ibuprofen	Ibuprofen	56	14
Metoprolol Succinate	Metoprolol Succinate	54	18
Carvedilol	Carvedilol	50	15
Pregabalin	Pregabalin	49	14
Trazodone Hcl	Trazodone Hcl	49	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	47	12
Meloxicam	Meloxicam	46	suppressed
Simvastatin	Simvastatin	45	13
Jardiance	Empagliflozin	43	14
Triamcinolone Acetonide	Triamcinolone Acetonide	43	14
Metformin Hcl Er	Metformin Hcl	39	13
Furosemide	Furosemide	38	12
Synjardy	Empagliflozin/Metformin Hcl	38	suppressed
Baclofen	Baclofen	34	suppressed
Breyna	Budesonide/Formoterol Fumarate	34	suppressed
Clopidogrel	Clopidogrel Bisulfate	34	11
Metoprolol Tartrate	Metoprolol Tartrate	33	11
Meclizine Hcl	Meclizine Hcl	32	suppressed
Spiriva Handihaler	Tiotropium Bromide	31	suppressed
Benazepril Hcl	Benazepril Hcl	30	suppressed
Duloxetine Hcl	Duloxetine Hcl	30	13
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	29	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	28	suppressed
Finasteride	Finasteride	27	suppressed
Spiriva Respimat	Tiotropium Bromide	27	suppressed
Atenolol	Atenolol	26	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	25	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	25	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	25	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	24	15
Januvia	Sitagliptin Phosphate	24	suppressed
Nifedipine Er	Nifedipine	24	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	23	suppressed
Terbinafine Hcl	Terbinafine Hcl	23	suppressed
Tizanidine Hcl	Tizanidine Hcl	23	suppressed
Clotrimazole	Clotrimazole	22	12
Eliquis	Apixaban	22	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	22	suppressed
Prednisone	Prednisone	22	suppressed
Celecoxib	Celecoxib	21	suppressed
Mirtazapine	Mirtazapine	21	suppressed
Topiramate	Topiramate	21	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	21	suppressed
Fluconazole	Fluconazole	20	17
Glipizide Er	Glipizide	20	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	20	suppressed
Lactulose	Lactulose	20	suppressed
Semglee (Yfgn) Pen	Insulin Glargine-Yfgn	20	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	20	suppressed
Colchicine	Colchicine	19	suppressed
Sertraline Hcl	Sertraline Hcl	19	suppressed
Montelukast Sodium	Montelukast Sodium	18	suppressed
Spironolactone	Spironolactone	18	suppressed
Azithromycin	Azithromycin	17	14
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	17	suppressed
Telmisartan	Telmisartan	17	suppressed
Valsartan	Valsartan	17	suppressed
Hydralazine Hcl	Hydralazine Hcl	16	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	16	suppressed
Breo Ellipta	Fluticasone/Vilanterol	15	suppressed
Citalopram Hbr	Citalopram Hydrobromide	15	suppressed
Clindamycin Phosphate	Clindamycin Phosphate	15	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	15	suppressed
Xarelto	Rivaroxaban	15	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	14	suppressed
Amoxicillin	Amoxicillin	14	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	14	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	14	suppressed
Rybelsus	Semaglutide	14	suppressed
Alprazolam	Alprazolam	13	suppressed
Chlorthalidone	Chlorthalidone	13	suppressed
Ketoconazole	Ketoconazole	13	suppressed
Lorazepam	Lorazepam	13	suppressed
Potassium Chloride	Potassium Chloride	13	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	13	suppressed
Symbicort	Budesonide/Formoterol Fumarate	13	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	12	suppressed
Ezetimibe	Ezetimibe	12	suppressed
Lidocaine	Lidocaine	12	suppressed
Loperamide	Loperamide Hcl	12	suppressed
Nitroglycerin	Nitroglycerin	12	suppressed
Paroxetine Hcl	Paroxetine Hcl	12	suppressed
Sucralfate	Sucralfate	12	suppressed
Tacrolimus	Tacrolimus	12	suppressed
Tiotropium Bromide	Tiotropium Bromide	12	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	12	suppressed
Alendronate Sodium	Alendronate Sodium	11	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	11	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	11	suppressed
Cephalexin	Cephalexin	11	suppressed
Estradiol	Estradiol	11	suppressed
Lamotrigine	Lamotrigine	11	suppressed
Novolin 70-30	Insulin Nph Hum/Reg Insulin Hm	11	suppressed
Nystatin	Nystatin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error